Bluejay Diagnostics (NASDAQ:BJDX) Director Acquires $25,000.00 in Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Fred Zeidman acquired 12,500 shares of the firm’s stock in a transaction dated Saturday, March 14th. The stock was purchased at an average cost of $2.00 per share, with a total value of $25,000.00. Following the transaction, the director owned 12,500 shares in the company, valued at approximately $25,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Bluejay Diagnostics Stock Up 3.0%

Shares of BJDX stock traded up $0.05 on Monday, reaching $1.72. The stock had a trading volume of 34,940 shares, compared to its average volume of 155,600. The firm’s 50-day moving average is $1.90 and its two-hundred day moving average is $3.24. The firm has a market capitalization of $1.77 million, a price-to-earnings ratio of -0.15 and a beta of 0.72. Bluejay Diagnostics, Inc. has a 12 month low of $1.63 and a 12 month high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.